The Centene Medicaid Managed Care class action represents one of the largest pharmacy benefit manager settlements in recent history, with the healthcare company agreeing to pay more than $1 billion across settlements with at least 20 states since 2021. These settlements stem from allegations that Centene’s pharmacy benefit manager (PBM) operations overcharged Medicaid programs, the joint federal-state health insurance program serving low-income individuals and families. California’s settlement alone reached $215 million in 2024, making it one of the most substantial recoveries for any state, while South Carolina secured a $25.89 million settlement for similar allegations.
The scale of these settlements underscores a critical issue in how prescription drugs are managed within government health programs. Despite settling with numerous states, Centene has admitted no wrongdoing in any of these cases, meaning the company paid these settlements without conceding to the allegations. For people who receive Medicaid coverage or for state programs stretching limited healthcare budgets, understanding what happened and how settlement funds are being returned is essential.
Table of Contents
- What Is the Centene Medicaid Pharmacy Benefit Manager Dispute?
- How Much Money Has Centene Paid in Settlements and Who Received It?
- What Were the Specific Allegations Against Centene’s Pharmacy Benefit Manager?
- How Do Settlement Distributions Work and Who Is Eligible?
- What Should You Know About Centene’s Denial of Wrongdoing?
- Why Is Centene’s Size Important to This Case?
- What’s Next for Centene and Medicaid PBM Oversight?
- Conclusion
What Is the Centene Medicaid Pharmacy Benefit Manager Dispute?
Centene is one of the largest healthcare companies in the United states, reporting $163 billion in revenue in 2024, with the vast majority coming from government health programs like Medicaid. As a Medicaid managed care provider, Centene also operates its own pharmacy benefit manager, which negotiates drug prices and processes prescription claims. The dispute centers on allegations that this PBM operation charged Medicaid programs excessive fees, inflated costs, or engaged in other billing practices that violated the terms of their contracts with state Medicaid agencies. Pharmacy benefit managers act as intermediaries between health insurers, pharmacies, and pharmaceutical manufacturers.
They negotiate rebates from drug makers, set formularies (lists of covered drugs), and process claims. When a PBM overcharges or engages in unfair billing practices, the costs cascade through the entire system—ultimately affecting the Medicaid programs that rely on them to keep prescription drug costs manageable. In Centene’s case, state attorneys general alleged that these practices resulted in systematic overcharges that drained state budgets meant for patient care. The controversy reflects a broader national conversation about PBM practices. Unlike some other major cases involving standalone PBMs, Centene’s situation is complicated by the fact that the company both operates Medicaid plans and the PBM serving those plans, creating potential conflicts of interest that regulators and state attorneys general found concerning.
How Much Money Has Centene Paid in Settlements and Who Received It?
California received the largest single settlement, with Attorney General Bonta announcing a $215 million agreement in 2024 for alleged Medicaid overbilling by Centene’s pharmacy benefit manager. This settlement represents California’s effort to recover funds that should have remained in the state’s Medicaid program to support beneficiaries and healthcare providers. South Carolina also successfully negotiated a settlement, securing $25.89 million for similar allegations of overcharging the state’s Medicaid program. Across more than 20 states, Centene has agreed to pay settlements totaling over $1 billion since 2021, demonstrating the breadth of the dispute.
However, a critical limitation of these settlements is that many states have not yet fully recovered or settled their cases. Georgia, for example, remains an outstanding case despite Centene indicating in 2022 that it was actively negotiating with Georgia and eight other states. This means the total settlement amount could increase if remaining states successfully conclude their negotiations. Some beneficiaries or state programs may still be waiting for distributions or may be subject to different settlement terms depending on which state’s agreement applies to them.
What Were the Specific Allegations Against Centene’s Pharmacy Benefit Manager?
The allegations against Centene’s pharmacy benefit manager operation centered on overcharging Medicaid programs, though the specific practices varied by state and case. State attorneys general alleged that Centene engaged in billing practices that violated contractual obligations or state law, resulting in Medicaid programs paying more than they should have for pharmacy services and prescription drugs. In some cases, the disputes involved claims that Centene failed to pass through rebates from drug manufacturers to state Medicaid programs as required.
Unlike cases involving publicly disclosed settlement details that break down specific allegations, Centene’s settlements have largely remained confidential in terms of the exact nature of the billing practices in question. This creates a limitation for beneficiaries and the public: the specific mechanics of how the overcharging occurred are not always transparent. What is clear from settlement announcements is that multiple independent state investigations—from California to South Carolina and beyond—identified systematic issues serious enough to warrant substantial financial settlements. The consistency across states suggests patterns rather than isolated billing errors.
How Do Settlement Distributions Work and Who Is Eligible?
Settlement distributions vary depending on which state’s settlement applies to you and the terms of that specific agreement. For beneficiaries, the key question is whether you receive a direct payment, whether your state’s Medicaid program retains the funds for program improvements, or whether a portion is distributed and a portion is retained. In some cases, states may use settlement funds to enhance beneficiary services, improve pharmacy networks, or reduce costs in other areas of the Medicaid program.
This creates a tradeoff: while individual beneficiaries may not see a direct check, the settlement money theoretically benefits the entire program and its participants over time. A critical deadline exists for at least one case: June 8, 2026 is the deadline to claim settlement funds in at least one class action, meaning eligible parties who do not take action by this date may lose the opportunity to recover their share. The definition of who is “eligible” depends entirely on the settlement terms—typically it includes people who were Medicaid beneficiaries during the period when Centene’s alleged overcharging occurred. If you or a family member received Medicaid coverage during the relevant time period and used pharmacy benefits, you may be eligible, but you need to verify the specific settlement terms in your state.
What Should You Know About Centene’s Denial of Wrongdoing?
An important limitation in understanding these settlements is that Centene admitted no wrongdoing in any of them. The company paid the settlements, but from a legal standpoint, the payments do not constitute an admission that the allegations are true. This is common in settlement agreements, particularly those involving large corporations and government entities, but it can be confusing for people trying to understand whether the overcharges actually occurred.
From the perspective of state attorneys general, the substantial settlement amounts and multiple simultaneous agreements across states suggest serious concerns, but the lack of admission means Centene maintains its position that its billing practices were proper. This distinction matters for any future litigation or public perception. If you are considering whether to pursue a claim or are questioning the validity of these settlements, understand that the financial outcome—over $1 billion in payouts—speaks to the regulators’ confidence in their cases, even without explicit admissions from the company. However, the absence of wrongdoing admissions also means beneficiaries cannot point to a court judgment or settlement agreement as definitive proof of overcharging in their communications with other entities or for other purposes.
Why Is Centene’s Size Important to This Case?
Centene’s massive revenue base—$163 billion in 2024, almost entirely derived from government health programs—provides important context for understanding the scale and significance of these settlements. A company of this size has enormous influence over prescription drug access and costs for millions of Medicaid beneficiaries nationwide. When even a portion of such a large healthcare system allegedly engaged in overcharging, the cumulative impact on state budgets and beneficiary access can be substantial.
The company’s size also explains why multiple states pursued these cases simultaneously and why settlements were worth pursuing. For smaller companies, the cost of litigation and settlement negotiation might not be worthwhile, but for a company handling government contracts worth hundreds of billions annually, significant settlements are a manageable business expense. This creates an incentive structure where companies may factually settle cases they dispute because the legal costs and risks make settlement economically rational, even without admitting fault.
What’s Next for Centene and Medicaid PBM Oversight?
As of 2026, the Centene settlements represent significant but incomplete resolution of PBM concerns in Medicaid. With some states still negotiating (like Georgia) and cases potentially continuing to unfold, the landscape remains dynamic.
These settlements may also influence how other states and the federal government approach PBM oversight, as they demonstrate that regulators can successfully challenge billing practices they view as unfair. Looking forward, Medicaid programs and state attorneys general are likely to continue scrutinizing PBM practices, particularly in cases where the PBM is owned by or affiliated with the Medicaid managed care plan it serves. The Centene case illustrates the complexity of pharmaceutical cost management in government programs and the ongoing tension between efficiency, cost containment, and fair dealing with beneficiaries and state budgets.
Conclusion
The Centene Medicaid Managed Care class action settlements represent a landmark moment in pharmaceutical industry oversight, with more than $1 billion in payments across at least 20 states addressing allegations of Medicaid overcharging. The largest single settlement, California’s $215 million agreement, underscores the scale of the issues identified by state attorneys general across the country.
These settlements are meaningful not only for the dollar amounts involved but also for the message they send about holding large healthcare companies accountable for their billing practices. If you received Medicaid coverage during the periods covered by these settlements, particularly in California, South Carolina, or any of the other states that have reached agreements with Centene, check the settlement details for your state and understand the eligibility requirements and deadlines. With at least one settlement deadline set for June 8, 2026, acting promptly on any potential claims is essential to protect your rights and ensure you do not miss the opportunity to recover any portion of these settlements that may be distributed to beneficiaries.